This study aims to develop and characterize a solid lipid nanoparticle (SLN) formulation for the anti-psychotics drug clozapine to improve drug delivery efficiency. Using a modified high-speed homogenization and ultra sonication method, the formulation was optimized through a central composite design, varying solid lipid weights, and surfactant amount. The optimized SLN formulation, consisting of 102.77 % glyceryl monosterate, 5.24 Compritol® 888%, and 3 % tween 80, resulted in particles with an average size of 275.30 nm, a PDI of 0.251±0.25, and a zeta potential of -19.2±0.11 mV. The entrapment efficiency was 97.15±0.25 %, and drug release was 98.06±0.14 % over 24 hours, showing an initial burst followed by sustained release. Scanning electron microscopy revealed spherical particles with porous surfaces. Kinetic analysis indicated a zero-order release mechanism with non-Fickian diffusion. Stability studies over 60 days under ICH guidelines showed no significant changes, confirming the formulation's stability.